Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
Arthritis & Rheumatism2010Vol. 63(3), pp. 609–621
Citations Over TimeTop 1% of 2010 papers
Joel M. Kremer, Ricardo Blanco, Marek Brzosko, Rubén Burgos‐Vargas, Anne-Marie Halland, Emma Vernon, Petra Ambs, Roy Fleischmann
Abstract
The findings of this study show that tocilizumab plus MTX results in greater inhibition of joint damage and improvement in physical function than does MTX alone. Tocilizumab has a well-characterized safety profile.
Related Papers
- → Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?(2015)31 cited
- Clinical, Radiographic, and Immunogenic Effects After 1 Year of Tocilizumab-Based Treatment Strategy with and without Methotrexate in Rheumatoid Arthritis: The ACT-RAY Study(2012)
- Is Actemra (tocilizumab) in Combination with Methotrexate an Effective Treatment for Rheumatoid Arthritis in Patients who had an Inadequate Response to Methotrexate Alone(2011)
- → Optimise: An Austrian Multicentre Study on the Effectiveness and Safety of Tocilizumab in Combination with Methotrexate versus Tocilizumab for Mild/Moderate Rheumatoid Arthritis and an Inadequate Response to Methotrexate(2019)
- Switch from Tocilizumab plus Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity(2015)